Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Celator Pharmaceuticals today announced that it has completed enrollment in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML). The target enrollment of 120 patients was reached in less than 11 months, nearly 3 months faster than anticipated.

"We are grateful to the patients who have entered this study and to the investigators and their teams whose enthusiasm and commitment made it possible to complete enrollment ahead of schedule," said Scott Jackson, chief executive officer of Celator Pharmaceuticals. "We look forward to presenting our first look at the data - what we hope will be additional evidence of the benefits of CPX-351 in this patient population - later this year at the American Society of Hematology."

The Phase 2 study enrolled patients with newly diagnosed AML, 60-75 years of age, who were able to tolerate intensive chemotherapy. This randomized (2:1) study is designed to compare CPX-351 to the standard of care, commonly referred to as "7+3." In the "7+3" regimen, cytarabine is administered as a 7 day continuous infusion and daunorubicin is administered on days 1, 2 and 3. CPX-351, containing both agents at a synergistic ratio, is infused over 90 minutes on days 1, 3 and 5. The primary endpoint of the study is complete remission rate. Secondary endpoints are duration of complete remission, event free survival, survival at 12 months, rate of stem cell transplant, 30, 60, and 90 day mortality, and safety and tolerability.

The Company plans to release interim safety and complete remission data from the first 80 evaluable patients at the 51st American Society of Hematology Annual Meeting, December 5-8, 2009, in New Orleans, Louisiana. In addition to the clinical study results, data will also be presented on the improved selectivity of CPX-351 for leukemic cells over normal bone marrow cells.


Celator Pharmaceuticals


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Pre- and post-surgical immunotherapy-based treatment significantly improved lung cancer outcomes